Table 2.

Characteristics of donor, recipient, and transplant factors in the no steroid group

CharacteristicsNo Steroid Induction CategoriesP Value
IL2-RAr-ATGAlemtuzumabBefore IPTWAfter IPTWa
N=15,617 (%)1515 (9.7)9378 (60)4724 (30.2)
Donors
 Age, yr38.9±17.136.6±16.938.6±16.5<0.0010.49
 Women, %39.040.240.20.66
 Race, %<0.001
  White69.670.669.1
  Black13.313.716.8
  Hispanic13.012.411.4
  Other4.13.32.7
 ECD, %2015.818.4<0.001
 KDPI, %47.4±28.644.8±27.447.3±27.6<0.0010.91
Recipients
 Age, yr56.3±14.352±1351.1±12.5<0.0010.004
 Women, %32.936.638.5<0.0010.62
 Race, %<0.0010.63
  White56.352.147.1
  Black21.325.434.1
  Hispanic12.213.513
  Other10.295.8
 DM (yes), %41.147.343.9<0.0010.93
 CVD (yes), %8.89.47.3<0.0010.51
 Retransplant, %5.17.46.40.0010.60
 Dialysis before transplant, %<0.0010.99
  Preemptive13.91614.4
  <1 yr5.64.93.4
  1–3 yr29.228.421.1
  >3 yr51.350.761.2
 PRA, %<0.0010.95
  0–2050.743.433.9
  21–8055.35
  81–1001.92.93.9
  Missing42.448.457.3
Transplants
 CIT, h16.7±8.717.8±9.617.6±8.3<0.0010.35
 Weight ratio D/R1.03±0.361.01±0.361.00±0.370.020.65
 HLA mismatch, %0.010.99
  12.41.72.5
  24.94.45.3
  313.51414
  427.729.129
  534.634.532.8
  61716.316.4
 Transplant year, %<0.0010.39
  2000–20013.90.40
  2002–20034.62.81.1
  2004–200515.611.58.1
  2006–200718.822.619.5
  2008–200923.62424.4
  2010–201233.538.646.9
  • IL2-RA, IL-2 receptor antagonist; r-ATG, rabbit antithymocyte globulin; IPTW, inverse probability of treatment weight; ECD, expanded criteria donor; KDPI, kidney donor profile index; DM, diabetes; CVD, cardiovascular disease; PRA, panel reactive antibody; CIT cold ischemia time; D/R, donor/recipient.

  • a Some of the P values are not reported, because those variables are not included in the propensity score analysis.